Patent Monopolies, Corruption And The New Alzheimer’s Drug – OpEd

It seems that no one in policy circles believes that people respond to incentives. How else can we explain this lengthy piece in the New York Times on the process by which the Food and Drug Administration (FDA)) approved Adehelm, a drug for treating Alzheimer’s disease.

The piece details how the clinical trials designed to...